Clinical Trial Update: Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating atezolizumab and bevacizumab with Y-90 radioembolization for unresectable hepatocellular carcinoma was terminated, with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: Aiwu Ruth He, MD | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2024-06-05